Oncology
Clinical research in advanced solid tumours, with interest in treatment settings where disease control remains limited and new systemic options are needed.
- Cancer
- Solid tumours
- Advanced malignancies
The sponsor’s active research focus includes clinical development in tumour-directed therapy and combination approaches involving immune checkpoint inhibitor treatment.
Immuno-oncology
Investigation of therapies paired with pembrolizumab reflects an interest in immune-based cancer treatment and the modulation of antitumour activity through checkpoint blockade.
- Immune checkpoint inhibitor
- Pembrolizumab
- Combination therapy
This area centres on integrating novel agents with established immunotherapy strategies for patients with selected advanced cancers.
Early-stage clinical development
The sponsor is engaged in first-in-patient evaluation of DT-7012, with attention to safety, tolerability, and dose identification in a monotherapy and combination setting.
- DT-7012
- Monotherapy
- Safety and tolerability
Research activity in this domain supports assessment of a new therapeutic candidate across both standalone and partnered oncology use cases.
Translational solid tumour therapeutics
The funded programme reflects interest in moving novel anti-cancer agents into clinical use for patients with selected advanced solid tumours, where treatment resistance and unmet need are prominent.
- Advanced solid tumours
- Anti-cancer agents
- Therapeutic innovation
Research sites in Australia support the sponsor’s oncology-focused programme in a single-country clinical setting.
